{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:08:45Z","timestamp":1761718125995,"version":"3.38.0"},"reference-count":69,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T00:00:00Z","timestamp":1264377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p> Crohn\u2019s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases which can be difficult to control with conventional therapies. A greater understanding of their pathophysiology has led to new therapies that target specific molecules of the inflammatory cascade. Three anti-tumor necrosis factor (TNF) monoclonal antibodies have been developed. Infliximab and adalimumab can induce clinical response and sustained remission in CD. Infliximab is also effective in UC. Certolizumab pegol gives good short-term results but long-term efficacy has yet to be determined in other clinical trials. Therapies that target leucocyte trafficking (anti-integrins) have also been developed and are associated with good clinical response in CD. Natalizumab (anti-\u03b14 integrin antibody) is associated with important side effects and is not used anymore in gastroenterology in Europe but is still used in the USA. Vedolizumab (MLN0002), an anti-\u03b14\u03b27 integrin antibody, has a good efficacy and safety profile. Monoclonal antibodies targeting other cytokines are also under development. For example, ustekinumab (CNTO 1275) inhibits interleukins 12 and 23. It is associated with a good clinical response in CD. <\/jats:p>","DOI":"10.1177\/1756283x09356872","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T01:25:34Z","timestamp":1264469134000},"page":"99-106","source":"Crossref","is-referenced-by-count":21,"title":["Review: Current directions of biologic therapies in inflammatory bowel disease"],"prefix":"10.1177","volume":"3","author":[{"given":"Catherine","family":"Reenaers","sequence":"first","affiliation":[{"name":"Gastroenterology, CHU Sart-Tilman, 4000 Li\u00e8ge, Belgium,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Belaiche","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, University of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,1,25]]},"reference":[{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"Baert, F., Noman, M., Vermeire, S., Van Assche, G., D\u2019Haens, G., Carbonez, A. et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 348: 601-608.","DOI":"10.1056\/NEJMoa020888"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.019"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-199902000-00007"},{"key":"atypb4","first-page":"667","volume":"152","author":"Berrebi, D.","year":"1998","journal-title":"Am J Pathol"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90402-X"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200207000-00002"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.045294"},{"key":"atypb9","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4049\/jimmunol.161.6.3143","volume":"161","author":"Davidson, N.J.","year":"1998","journal-title":"J Immunol"},{"key":"atypb10","doi-asserted-by":"crossref","unstructured":"D\u2019Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H. et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. Lancet 371: 660-667.","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.2174\/157488706778250168"},{"key":"atypb12","unstructured":"Faubion Jr, W.A., Loftus Jr, E.V., Harmsen, W.S., Zinsmeister, A.R. and Sandborn, W.J. ( 2002) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 123: 393-395."},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042982"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.06.007"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20229"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.495"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020732"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01205.x"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26260"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.015"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2005.01.001"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.003"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.012"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.003"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40036.x"},{"key":"atypb29","doi-asserted-by":"crossref","unstructured":"Korzenik, J.R., Dieckgraefe, B.K., Valentine, J.F., Hausman, D.F. and Gilbert, M.J. Sargramostim in Crohn\u2019s Disease Study Group. ( 2005) Sargramostim for active Crohn\u2019s disease. N Engl J Med 352: 2193-2201.","DOI":"10.1056\/NEJMoa041109"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)80068-P"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.031"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.03.002"},{"key":"atypb33","doi-asserted-by":"crossref","unstructured":"Louis, E., Collard, A., Oger, A.F., Degroote, E., Aboul Nasr El Yafi, F.A. et al. (2002) Behaviour of Crohn\u2019s disease according to the Vienna classification: changing pattern over the course of the disease . Gut 51: 614-615.","DOI":"10.1136\/gut.51.4.614"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033402"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230923"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70128-8"},{"key":"atypb37","doi-asserted-by":"crossref","unstructured":"Moore, K.W., de Waal Malefyt, R., Coffman, R.L. and O\u2019Garra, A. ( 2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.","DOI":"10.1146\/annurev.immunol.19.1.683"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.3109\/00365529509096316"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.5.1281"},{"key":"atypb40","first-page":"823","volume":"150","author":"Parronchi, P.","year":"1997","journal-title":"Am J Pathol"},{"key":"atypb41","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i16.2328"},{"key":"atypb42","doi-asserted-by":"crossref","unstructured":"Plevy, S., Salzberg, B., Van Assche, G., Regueiro, M., Hommes, D., Sandborn, W. et al. (2007) A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis . Gastroenterology 133: 1414-1422.","DOI":"10.1053\/j.gastro.2007.08.035"},{"key":"atypb43","doi-asserted-by":"crossref","unstructured":"Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., van Hogezand, R.A. et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 340: 1398-1405.","DOI":"10.1056\/NEJM199905063401804"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.5.684"},{"key":"atypb45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb05997.x"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.070"},{"key":"atypb48","doi-asserted-by":"crossref","unstructured":"Sandborn, W.J., Feagan, B.G., Fedorak, R.N., Scherl, E., Fleisher, M.R., Katz, S. et al. (2008) A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology 135: 1130-1141.","DOI":"10.1053\/j.gastro.2008.07.014"},{"key":"atypb49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"atypb52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08703.x"},{"key":"atypb53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"atypb54","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200501000-00003"},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20196"},{"key":"atypb56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"atypb57","doi-asserted-by":"crossref","unstructured":"Schreiber, S., Rutgeerts, P., Fedorak, R.N., Khaliq-Kareemi, M., Kamm, M.A., Boivin, M. et al. e (2005) CDP870 Crohn\u2019s Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn\u2019s disease. Gastroenterology 129: 807-818.","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"atypb58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02309.x"},{"key":"atypb59","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000194185.69800.07"},{"key":"atypb60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013136"},{"key":"atypb61","doi-asserted-by":"publisher","DOI":"10.1007\/BF01300378"},{"key":"atypb62","doi-asserted-by":"crossref","unstructured":"Targan, S.R., Hanauer, S.B., van Deventer, S.J., Mayer, L., Present, D.H., Braakman, T. et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 337: 1029-1035.","DOI":"10.1056\/NEJM199710093371502"},{"key":"atypb63","doi-asserted-by":"crossref","unstructured":"ten Hove, T., van Montfrans, C., Peppelenbosch, M.P. and van Deventer, S.J. ( 2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease. Gut 50: 206-211.","DOI":"10.1136\/gut.50.2.206"},{"issue":"7","key":"atypb64","first-page":"1160","volume":"24","author":"Trinder, M.W.","journal-title":"J Gastroenterol Hepatol"},{"key":"atypb65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051586"},{"key":"atypb66","doi-asserted-by":"crossref","unstructured":"Van den Brande, J.M., Braat, H., van den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I. et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology 124: 1774-1785.","DOI":"10.1016\/S0016-5085(03)00382-2"},{"key":"atypb67","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/gut.2005.072793","volume":"55","author":"Wolters, F.L.","year":"2006","journal-title":"Gut"},{"key":"atypb68","doi-asserted-by":"crossref","unstructured":"Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie., B, et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116: 1310-1316.","DOI":"10.1172\/JCI21404"},{"key":"atypb69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054693"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X09356872","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X09356872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T12:02:29Z","timestamp":1740830549000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756283X09356872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,25]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1177\/1756283X09356872"],"URL":"https:\/\/doi.org\/10.1177\/1756283x09356872","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"type":"print","value":"1756-2848"},{"type":"electronic","value":"1756-2848"}],"subject":[],"published":{"date-parts":[[2010,1,25]]}}}